Woodline Partners’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TGTX
VPM
VCM
SCM
CAM
Woodline Partners's TGTX Position: Q1 2026 in Review
Woodline Partners opened a new position in TG Therapeutics (TGTX) in Q1 2026: 715,500 shares worth $23.8M. The stake represents 0.09% of the portfolio and ranks #297 among its holdings. This is a return to the name: Woodline Partners previously reported a position in TGTX as recently as Q2 2025.
Woodline Partners first reported a position in TGTX in Q2 2020 and has held it in 17 quarters since. The position peaked at $60M in Q3 2024. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.
- Woodline Partners held 715,500 shares of TG Therapeutics worth $23.8M as of Q1 2026.
- TG Therapeutics was a new Woodline Partners position in Q1 2026.
- TG Therapeutics made up 0.09% of Woodline Partners's portfolio in Q1 2026, its #297 holding.
- Woodline Partners first reported a position in TG Therapeutics in Q2 2020 and has held it in 17 quarters since.
- Woodline Partners's TG Therapeutics position peaked at $60M in Q3 2024.
- 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.
Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.